期刊文献+

两种钙调磷酸酶抑制剂联合常用抗真菌药物对马尔尼菲青霉酵母相体外药敏的研究 被引量:3

THE STUDY OF THE DURG SENSITIVITY OF TWO KINDS OF CLACINEURIN INHIBITORS COMBINED WITH COMMON ANTIFUNGAL DRUG PENICILLIUM MARNEFFEI ON THE YEAST PHASE
下载PDF
导出
摘要 目的:探讨两种钙调磷酸酶抑制剂联合常用抗真菌药物,对20株马尔尼菲青霉(PM)酵母相体外药敏的作用。方法:参照美国临床和实验室标准协会(CLSI)M27-A3方案并做适当修改,采用棋盘格微量稀释法对20株PM酵母相进行钙调磷酸酶抑制剂环孢素A(CsA)、他克莫司(FK506)与5种常用抗真菌药物联合的体外药敏实验。结果:CsA与两性霉素B(AmB)、伊曲康唑(ITC)、氟康唑(FLC)联合时,各药的最低抑菌浓度(MIC)值均比单用时明显降低(均P<0.05)。CsA与AmB、ITC、FLC联合,分别有17株(85%)、13株(65%)、6株(30%)的菌株显示协同作用;而CsA与米卡芬净(MCFG)、卡泊芬净(CPFG)联合所有菌株均表现为无关联作用。FK506与以上5种抗真菌药联合时,各药物的MIC值较单用时无明显变化,联合时呈无关联作用。在所有受试PM酵母相中,CsA及FK506与以上5种抗真菌药物联合均未出现拮抗作用。结论:体外药敏研究显示,CsA与FK506在体外联合药敏中作用不同,CsA可增强AmB、ITC、FLC对PM酵母相的抗真菌活性;但FK506则无此作用。 Objective:To evaluate the in vitro interaction effects of two kinds of calcineurin inhibitors combined with antifungal agents against on the pathogenic yeast form of P. Marneffei(PM). Methods: according to American clinical and Laboratory Standards Institute (CLSI) M27-A3 scheme , the scheme was made appropriate modifications. Then 20 strains of PM yeast phase of calcineurin inhibitors cyclosporine was performed durg sensitivity tests with checkerboard microdilution method bt (CsA), tacrolimus (FK506) combined with 5 kinds of commonly used antifungal drugs in vitro. Results: the MIC effectof CsA with amphotericin B (AmB), or itraconazole (ITC) or fluconazole (FLC) were significantly lower than the single use (P 〈 0.05). When CsA respectively combined with AmB, ITC, FLC, the synerigistic rate of them respeci- tively were 85%, 65%, and 30^; But there was no role on yests when the CsA respectively combined with micafungin (MCFG),or caspofungin (CPFG). Meanwhile, no synergism was observed in the combinations of tacrolimus(FK506) with other five antifungal agents. No antagonism was observed for any of the anti- fungal combinations assayed in the study. Conclusion. in vitro susceptibility studies show, CsA and FK506 in different in vitro drug sensitivity in CsA, ITC, FLC, AmB can enhance the antibacterial activity of the yeast phase of PM. But FK506 didn't have such effects. Conclusion;The research showed that CsA could en- hance the activity of AmB,ITC,FLC against the yeast form of PM. FK506 did not exert synergistic activity with any of the five antifungal agents used in this study, further researches are required to the mechanism.
出处 《广西医科大学学报》 CAS 2015年第2期169-172,共4页 Journal of Guangxi Medical University
基金 国家自然科学基金资助项目(No.81060128和81271804) 广西自然科学基金资助项目(No.2012GXNSFAA053109026) 广西壮族自治区卫生厅自筹经费课题(No.Z2007082)
关键词 钙调磷酸酶抑制剂 体外联合药敏试验 马尔尼菲青霉 抗真菌药物 penicillium marneffei~ calcineurin inhibitors ~ combined therapy ~ antifungal susceptibility
  • 相关文献

参考文献11

  • 1Cao C,Liang L, Wang W,et al. Common reservoirs for Penicillium marneffei infection in humans and rodents, China[J]. Emerg Infect Dis,2011,17(2) : 209-Z14.
  • 2马坚池,席丽艳,胡永轩.马尔尼菲青霉病治疗进展[J].皮肤性病诊疗学杂志,2010,17(1):64-67. 被引量:11
  • 3Wu TC, Chan JW, Ng CK, et al. Clinical presentations and outcomes of Penicillium marneffei infeetions:a se- ries from 1994 to 2004[J]. Hong Kong Med J, 2008, 14(2) :103 109.
  • 4Cao C, Liu W, Li R, et al. In vitiro interactions of mieaf- ungin with amphotericin B, ITCaconazole or fluconazole against the pathogenic phase of Penieillium marneffei ~J3. J Antimicrob Chemother, 2009,63 (2) : 340-342.
  • 5Wayne P. Reference method for broth dilution antifun- gal susceptibility testing of yeasts. CLSI M27-Ag(-M~. 3rd ed. USA:Clinical and Laboratory Standards Institu- te(CLSI) ,2008 .. 1-25.
  • 6Sun S, Li Y,Guo Q,et al. In vitro interactions between taerolimus and azoles against Candida albieans deter mined by different methods [J]. Antimicrob Agents Chemother, 2008,52(2) :409-417.
  • 7Uppuluri P, Nett J, Heitman J, et al. Synergistic effect of Calcineurin inhibitors and fluconazole against Candi- da albicans biofilmsVJ~. Antimicrob Agents Chemoth- er,2008,52(3)~1 127-1 132.
  • 8Steinbach WJ, Singh N, Miller JL, et al. In vitro interac- tions between antifungals and immunosuppressants a- gainst Aspergillums fumigatus isolates from transplant and nontransplant patients E J~. Antimicrob Agents Chemother, 2004,48(12) :4 922-4 925.
  • 9Nareddy S, Manavathu E, Chandrasekar P, et al. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against Zygameetes [J]. J Antimierob Chemother ,2010 ,65 ( 4 ) =701-703.
  • 10Campo5 CB~ Di Benedette JP ~ Morais FV, et al. Evidence for the Role of Caleineurin in Morphogenesis and Calci- um Homeostasis during Mycelium-to-Yeast Dimor- phism of Paracoceidioides hrasiliensis EJ 1. Eukaryot Ce11,2008,7(10) :1 856-1 864.

二级参考文献21

  • 1李军,席丽艳,刘红芳,张军民,李希清,徐晓容.巨噬细胞内马尔尼菲青霉异柠檬酸裂解酶的表达[J].南方医科大学学报,2007,27(5):631-633. 被引量:4
  • 2Toru N,Jun U,Fumiaki I,et al.In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi:Comparison of Yeast-Like and Mycelial Forms[J].ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2003,47(4):1376-1381.
  • 3Cao C,Liu W,Li R,et al.In vitro interactions of micafungin with amphotericin B,itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei[J].J Antimicrob Chemother,2009,63(2):340-342.
  • 4Hondel CVD.Fungal cell wall biosynthesis and discovery of antifungals[M].The Congress Handbook&Abstract Book 2 of The 8th International Mycological Congress in Cairns,Australia on August,2006,318:20-25.
  • 5Kao RT,Lee SW,Madar JCS,et al.Identification of novel small molecular compounds that diferentially inhibit the yeast form of Penicillium marnefei[M].The Congress Handbook&Abstract Book 2 of The 8th International Mycological Congress in Cairns,Australia on August,2006,336:20-25.
  • 6Xi L,Xu X,Liu W,et al.Differentially expressed proteins of pathogenic Penicilliun marneffei in yeast and mycelial phases[J].J Med Microbiol,2007,56(3):298-304.
  • 7Hongfang L,Liyan X,Junmin Z,et al.Identifying differentially expressed genes in the dimorphic fungus Penicillium marneffei by suppression subtractive hybridization[J].FEMS Microbiol Lett,2007,270(1):97-103.
  • 8Wong KH,Lee SS,Chan KC.Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong[J].Hong Kong Med J,2006,12(2):133-140.
  • 9Cooper CR,Vanittanakom N.Insights into the pathogenicity of Penicillium marneffei[J].Future Microbiol,2008,3(1):43-55.
  • 10Cooper CR Jr,McGinnis MR.Pathology of Penicillium marneffei.An emerging acquired immunodeficiency syndrome-related pathogen[J].Arch Pathol Lab Med,1997,121(8):798-804.

共引文献10

同被引文献15

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部